Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | PTGIR | P43119 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818461 | 0.92 | EPHX2 (0.44) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL1622971 | 0.92 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL5847171 | 0.91 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3820525 | 0.91 | FABP5 (0.46) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3812973 | 0.91 | PTGIR (0.43) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3817315 | 0.91 | PTGIR (0.43) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL12155397 | 0.90 | FABP5 (0.48) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL7690563 | 0.89 | FABP5 (0.45) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3822341 | 0.89 | EPHX2 (0.53) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL27696345 | 0.89 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106188231-B | Synthesis and application of pasireotide pentapeptide intermediate | 中国医学科学院药物研究所 | 2021-10-22 | — | — | CN | claimed |
| CN-106188231-A | The synthesis of pasireotide pentapeptide intermediate and application | 中国医学科学院药物研究所 | 2016-12-07 | — | — | CN | claimed |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-20260036595-A1 | STRUCTURE-BASED PEPTIDES FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES IN PREECLAMPSIA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250362310-A1 | STRUCTURE-BASED PROBE FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-27 | — | — | US | disclosed |
| EP-3727462-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLERD LTD (GB) | 2025-11-05 | — | — | EP | disclosed |
| EP-4582436-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BicycleTX Limited (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-3727461-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2025-07-09 | — | — | EP | disclosed |
| CN-115066417-B | Factor XIa inhibitors | 上海京新生物医药有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4526323-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-03-26 | — | — | EP | disclosed |
| US-5763570-A | Glutathione analogs and paralog panels comprising glutathione mimics | TERRAPIN TECHNOLOGIES, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1997040034-A1 | SOLID PHASE AND COMBINATORIAL SYNTHESIS OF SUBSTITUTED THIOPHENES AND OF ARRAYS OF SUBSTITUTED THIOPHENES | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997040030-A1 | SOLID PHASE AND COMBINATORIAL SYNTHESIS OF SUBSTITUTED 2-METHYLENE-2,3-DIHYDROTHIAZOLES AND OF ARRAYS OF SUBSTITUTED 2-METHYLENE-2,3-DIHYDROTHIAZOLES | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997040025-A1 | SOLID PHASE AND COMBINATORIAL SYNTHESIS OF SUBSTITUTED 1,2,3-TRIAZOLES AND OF ARRAYS OF SUBSTITUTED 1,2,3-TRIAZOLES | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
| US-5679643-A | USUFUL AS CHROMATOGRAPHIC AFFINITY LIGANDS, BINDING REAGENTS, AND ENZYME INHIBITOR | TERRAPIN TECHNOLOGIES, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| US-5599903-A | TRIPEPTIDE; LIGAND, ENZYME INHIBITOR | TERRAPIN TECHNOLOGIES, INC. (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0720620-A1 | GLUTATHIONE ANALOGS AND PARALOG PANELS COMPRISING GLUTATHIONE MIMICS | TERRAPIN TECHNOLOGIES, INC. (US) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008563-A1 | GLUTATHIONE ANALOGS AND PARALOG PANELS COMPRISING GLUTATHIONE MIMICS | TERRAPIN TECHNOLOGIES, INC. (US) | 1995-03-30 | — | — | WO | disclosed |
| EP-0645397-A1 | Glutathione analogs and paralog panels comprising glutathione mimics | TERRAPIN TECHNOLOGIES, INC. (US) | 1995-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | KMT2A 1052/4885FABP5 2537/4885FABP7 2103/4885 |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | EPHA2, EPHB2, ERBB2 | KMT2A 1304/4885FABP5 2727/4885FABP7 1978/4885 |
| US-20260036595-A1 | STRUCTURE-BASED PEPTIDES FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES IN PREECLAMPSIA | TTR, APP, SERPINA3 | KMT2A 4282/4885FABP5 115/4885FABP7 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.